Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
BMC Infect Dis ; 24(1): 939, 2024 Sep 09.
Artículo en Inglés | MEDLINE | ID: mdl-39251918

RESUMEN

BACKGROUND: Corynebacterium striatum (C. striatum) is a gram-positive, anaerobic bacillus found both environmentally and in human skin and nasal mucosa flora. It is reportedly the etiologic agent of community-acquired and nosocomial diseases and is significantly associated with bacteremia and medical endovascular devices. This is the rare case of mitral valve native valve endocarditis (NVE) caused by C. striatum occurring in a young adult without underlying structural heart disease or indwelling cardiovascular medical devices successfully treated with multidisciplinary therapy. CASE PRESENTATION: The patient was a 28-year-old female with no medical history. She was transferred our hospital due to sudden onset of vertigo and vomit. A computed tomography on day 2 revealed the hydrocephalus due to the cerebellar infarction, and she underwent posterior fossa decompression for cerebellar infarction. An angiography on day 8 revealed a left vertebral artery dissection, which was suspected be the etiology. Afterwards, a sudden fever of 39 degrees developed on day 38. She was diagnosed with aspiration pneumonia and treated with ampicillin/sulbactam but was still febrile at the time of transfer for rehabilitation. Treatment continued with levofloxacin, the patient had no fever decline, and she was readmitted to our hospital. Readmission blood cultures (3/3 sets) revealed C. striatum, and an echocardiogram revealed an 11 mm long mitral valve vegetation, leading to NVE diagnosis. On the sixth illness day, cardiac failure symptoms manifested. Echocardiography revealed mitral valve rupture. She was transferred again on the 11th day of illness, during which time her mitral valve was replaced. C. striatum was detected in the vegetation. Following surgery, she returned to our hospital, and vancomycin administration continued. The patient was discharged after 31 total days of postoperative antimicrobial therapy. The patient experienced no exacerbations thereafter. CONCLUSIONS: We report the rare case of C. striatum mitral valve NVE in a young adult without structural heart disease or indwelling cardiovascular devices. CLINICAL TRIAL NUMBER: Not applicable.


Asunto(s)
Antibacterianos , Infecciones por Corynebacterium , Corynebacterium , Endocarditis Bacteriana , Humanos , Femenino , Adulto , Infecciones por Corynebacterium/microbiología , Infecciones por Corynebacterium/tratamiento farmacológico , Corynebacterium/aislamiento & purificación , Endocarditis Bacteriana/microbiología , Endocarditis Bacteriana/tratamiento farmacológico , Antibacterianos/uso terapéutico , Válvula Mitral/cirugía , Válvula Mitral/microbiología
2.
World J Gastroenterol ; 30(18): 2402-2417, 2024 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-38764770

RESUMEN

Viral hepatitis represents a major danger to public health, and is a globally leading cause of death. The five liver-specific viruses: Hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus, each have their own unique epidemiology, structural biology, transmission, endemic patterns, risk of liver complications, and response to antiviral therapies. There remain few options for treatment, in spite of the increasing prevalence of viral-hepatitis-caused liver disease. Furthermore, chronic viral hepatitis is a leading worldwide cause of both liver-related morbidity and mortality, even though effective treatments are available that could reduce or prevent most patients' complications. In 2016, the World Health Organization released its plan to eliminate viral hepatitis as a public health threat by the year 2030, along with a discussion of current gaps and prospects for both regional and global eradication of viral hepatitis. Today, treatment is sufficiently able to prevent the disease from reaching advanced phases. However, future therapies must be extremely safe, and should ideally limit the period of treatment necessary. A better understanding of pathogenesis will prove beneficial in the development of potential treatment strategies targeting infections by viral hepatitis. This review aims to summarize the current state of knowledge on each type of viral hepatitis, together with major innovations.


Asunto(s)
Antivirales , Hepatitis Viral Humana , Humanos , Antivirales/uso terapéutico , Hepatitis Viral Humana/epidemiología , Hepatitis Viral Humana/virología , Hepatitis Viral Humana/terapia , Hepatitis Viral Humana/diagnóstico , Virus de Hepatitis/patogenicidad , Virus de Hepatitis/efectos de los fármacos , Virus de Hepatitis/genética , Prevalencia , Hígado/virología , Hígado/patología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda